Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
about
The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disordersNeuroimmune basis of methamphetamine toxicityTreatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month periodThe anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments.Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody ResponseFirst human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteersChronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine.PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.
P2860
Q26777952-81D17DCB-F438-45C9-8C1B-E359A604B43EQ28247084-61E79272-8990-450E-95DE-6416A7F682BEQ33942970-4471E2CB-ED54-4E1F-8584-C86A249529AAQ34602548-908B562E-053F-49E7-B230-FA87F8D3A270Q35151502-C9DDAFFF-643F-4684-A932-5FA2A8E6E500Q35498227-997E3D72-1213-4E79-9D3E-3284923C346FQ35837611-0A0FBD69-6547-4341-88E0-56D710F67746Q36148294-45DE4F1C-F447-4DF2-B569-4C2E991B24A7Q36215915-000F15FF-0F92-4EF8-A0F4-F3B4D14810C7Q37264923-92E46393-D70B-428A-B216-F814B839BB30Q50548841-B6C8A545-FA22-4AB9-A383-C3D616ECFCAEQ53891489-1C3BCB99-0364-40F9-B804-32C142E681C4Q55471442-F9D50A34-01A8-4AAF-80C4-9E83E91E8983
P2860
Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical characterization o ...... clonal antibody for human use.
@en
Preclinical characterization o ...... clonal antibody for human use.
@nl
type
label
Preclinical characterization o ...... clonal antibody for human use.
@en
Preclinical characterization o ...... clonal antibody for human use.
@nl
prefLabel
Preclinical characterization o ...... clonal antibody for human use.
@en
Preclinical characterization o ...... clonal antibody for human use.
@nl
P2093
P2860
P356
P1476
Preclinical characterization o ...... clonal antibody for human use.
@en
P2093
Alicia D Kight
C Michael West
Misty W Stevens
Rachel L Tawney
Ralph L Henry
S Michael Owens
W Brooks Gentry
P2860
P304
P356
10.4161/MABS.27620
P577
2013-12-23T00:00:00Z